top of page

Pharmacogenetics’ Place in Personalized Medicine

Lauren Wilkes
Iota Class

image.png
image.png

.

When we get a prescription, we consider allergies, efficacy, etc. We don’t often sit in a hospital and consider whether our unique genetic variations may actually impact our body’s ability to process and metabolize a given medication. However, maybe we should, and there is, in fact, a field that does. 

 

Pharmacogenomics studies the way in which genetic variation in patients affects drug response in the body [1]. This field is vital for identifying genetic markers that indicate differences in the way people metabolize drugs. It is further integral in developing genetic tests that can help predict how patients will respond to these drugs. In so many of the drugs and therapies that are prescribed and provided, even as prominent as chemotherapy, there are cases in which patients have adverse reactions. While adverse reactions may be compiled as simple side effects, or  attributed to other explanations as to why a drug or treatment is less effective, some patients may actually have a genetic marker that could have helped identify the risk of said reaction sooner, with premature pharmacogenetic testing. 

 

While this may seem niche or a worry far from many, this phenomena can be seen in drugs that are much more common than one may think. Warfarin, for instance, is one of the most widely prescribed blood-thinning drugs in the world to treat and prevent thromboembolisms. As of a 2025 report, Warfarin prescriptions account for approximately eight million prescriptions in the United States annually [2]. 

 

In the human body, the gene, Warfarin metabolism relies on a pathway in which the VKORC1 and CYP2C9 genes are both implicated. While it is well known and common that there are external factors that respond to Warfarin dosing and treatment such as age, weight, sex, diet, etc., a significant underlying factor is the pharmacogenetic component. The CYP2C9 and VKORC1 genes have multiple variants within the population. These variants between the same gene can, in actuality, drastically impact the metabolism response by the body to Warfarin. For example, for the two variants of CYP2C9, Warfarin metabolism is reduced by 40% in patients with one variant and by 90% in those with the other [3].

 

Similar phenomena can be seen in antidepressants. A 2025 study by the European Journal of Human Genetics found that genetic factors have been estimated to account for up to 42% of the variability in antidepressant treatment response. In looking at four antidepressants, such as Escitalopram, they found individuals with variants of the relevant gene CYP2C19 involved in metabolism, were 49% more likely to report side effects of the medication [4]. 

 

Individuals’ genetic makeups influencing their responses to their medication is something that will likely be making its way to the forefront of personalized medicine. Each time we sit in a doctor’s office, and experience side effects while treating conditions, knowing that the side effects we experience are not completely arbitrary or expected for everyone, significantly helps in developing a treatment plan that centers us as the patients. 

 

  1. Loucks, C. M., Groeneweg, G., Roy, C., Lee, D. K., Rieder, M. J., Lebel, D., Ito, S., Ross, C. J., & Carleton, B. C. (2020). Pharmacogenomic testing: Enhancing personalized medication use for patients. Canadian family physician Medecin de famille canadien, 66(4), 241–243.

  2. Hong, H., Wilson, A. S., Jones, A. E., Vazquez, S. R., Gilbert, S., Malone, D. C., Chaiyakunapruk, N., King, J. B., Barnes, G. D., Sylvester, K. W., Dube, G., Irving, N. V., Chan, L., Ragheb, B., Delate, T., & Witt, D. M. (2025). Overcoming Barriers to Warfarin Patient Self-Management (PSM) in the US Healthcare System: Implementation Trial Study Protocol. medRxiv : the preprint server for health sciences, 2025.08.18.25333912. https://doi.org/10.1101/2025.08.18.25333912

  3. Rouse, M., Cristiani, C., & Teng, K. A. (2013). Q: Should we use pharmacogenetic testing when prescribing warfarin? Cleveland Clinic Journal of Medicine, 80(8), 483–486. https://doi.org/10.3949/ccjm.80a.12184

  4. Kariis, H.M., Särg, D., Krebs, K. et al. Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank. Eur J Hum Genet 33, 1376–1385 (2025). https://doi.org/10.1038/s41431-025-01894-x

bottom of page